Patents by Inventor C. Anthony Hunt
C. Anthony Hunt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6884577Abstract: The present invention provides novel assay methods for identifying compounds that may have both estrogen agonist and antagonist properties. In particular, the assay use cells comprising promoters having an AP1 site linked to a reporter gene. Compounds capable of inducing or blocking expression of the reporter gene can thus be identified. The compounds may be further tested for the ability to modulate the standard estrogen response, as well.Type: GrantFiled: December 4, 2000Date of Patent: April 26, 2005Assignee: The Regents of the University of CaliforniaInventors: Peter Kushner, Paul Webb, Renee Williard, C. Anthony Hunt, Gabriella Lopez
-
Patent number: 6410721Abstract: The invention is directed to a newly discovered class of polynucleotide decoys that is capable of competitively inhibiting the binding of transcription factors to the X-box sequence. This binding is necessary for the expression of MHC-II genes. The invention is also directed to methods of preparing these polynucleotide decoys, and methods of use thereof. In particular, we have identified a class of polynucleotide decoys that mimic the X-Box of MHC-II and competitively bind the MHC-II transcription factor RF-X, resulting in the modulation of MHC-II antigen expression. Thus, the invention can be used to inhibit the expression of HLA molecules on the surface of donor cells or organs, in order to render them invisible to the host's immune system, or in methods of treating an individual with an autoimmune disease characterized by dysfunctional expression of an MHC class II antigen.Type: GrantFiled: January 5, 1999Date of Patent: June 25, 2002Assignee: The Regents of the University of CaliforniaInventors: C. Anthony Hunt, Carol Lim, Marvin R. Garovoy
-
Publication number: 20010021532Abstract: The present invention provides novel assay methods for identifying compounds that may have both estrogen agonist and antagonist properties. In particular, the assay use cells comprising promoters having an AP1 site linked to a reporter gene. Compounds capable of inducing or blocking expression of the reporter gene can thus be identified. The compounds may be further tested for the ability to modulate the standard estrogen response, as well.Type: ApplicationFiled: December 4, 2000Publication date: September 13, 2001Inventors: Peter Kushner, Paul Webb, Renee Williard, C. Anthony Hunt, Gabriella Lopez
-
Patent number: 6156723Abstract: The present invention provides novel assay methods for identifying compounds that may have both estrogen agonist and antagonist properties. In particular, the assay use cells comprising promoters having an AP1 site linked to a reporter gene. Compounds capable of inducing or blocking expression of the reporter gene can thus be identified. The compounds may be further tested for the ability to modulate the standard estrogen response, as well.Type: GrantFiled: January 12, 1998Date of Patent: December 5, 2000Assignee: The Regents of the University of CaliforniaInventors: Peter Kushner, Paul Webb, Renee Williard, C. Anthony Hunt, Gabriella Lopez
-
Patent number: 5859226Abstract: The invention is directed to a newly discovered class of polynucleotide decoys that is capable of competitively inhibiting the binding of transcription factors to the X-box sequence. This binding is necessary for the expression of MHC-II genes. The invention is also directed to methods of preparing these polynucleotide decoys, and methods of use thereof. In particular, we have identified a class of polynucleotide decoys that mimic the X-Box of MHC-II and competitively bind the MHC-II transcription factor RF-X, resulting in the modulation of MHC-II antigen expression. Thus, the invention can be used to inhibit the expression of HLA molecules on the surface of donor cells or organs, in order to render them invisible to the host's immune system, or in methods of treating an individual with an autoimmune disease characterized by dysfunctional expression of an MHC class II antigen.Type: GrantFiled: July 27, 1994Date of Patent: January 12, 1999Assignee: Regents of the University of California, TheInventors: C. Anthony Hunt, Carol Lim, Marvin R. Garovoy
-
Patent number: 5723291Abstract: The present invention provides novel assay methods for identifying compounds that may have both estrogen agonist and antagonist properties. In particular, the assay use cells comprising promoters having an AP1 site linked to a reporter gene. Compounds capable of inducing or blocking expression of the reporter gene can thus be identified. The compounds may be further tested for the ability to modulate the standard estrogen response, as well.Type: GrantFiled: March 27, 1995Date of Patent: March 3, 1998Assignee: The Regents of the University of CaliforniaInventors: Peter Kushner, Paul Webb, Renee Williard, C. Anthony Hunt, Gabriella Lopez
-
Patent number: 5624803Abstract: The present invention encompasses improved methods and materials for the delivering of antisense, triplex, and/or ribozyme oligonucleotides intracellularly, and RNA polymerase III-based constructs termed "oligonucleotide generators" to accomplish the delivery of oligonucleotides. Also encompassed by the present invention are methods for screening oligonucleotide sequences that are candidates for triplex formation.Type: GrantFiled: October 13, 1994Date of Patent: April 29, 1997Assignee: The Regents of the University of CaliforniaInventors: Sarah B. Noonberg, C. Anthony Hunt
-
Patent number: 4612370Abstract: Functional oxygen transport systems (OTS) have been devised which may serve as temporary blood substitutes in the circulatory system. The OTS comprises pure crystalline hemoglobin dissolved in an aqueous solution and encapsulated within a complex lipid and carbohydrate modified lipid phase. The hemoglobin encapsulated inner aqueous phase and the encapsulating lipid phase are dispensed in an outer isotonic aqueous phase to form a suspension of the multiple water-in-oil-in water emulsion type. The emulsion is suitable to transfusion into the circulatory system to assist in oxygen transport. The carbohydrate modified lipids are included in the lipid phase to "mask" the OTS from the tissue binding and take up by the reticuloendothelial system. The OTS are also suitable for use as calibrating fluids in gas analysis apparatus.Type: GrantFiled: December 7, 1983Date of Patent: September 16, 1986Assignee: The Regents of the University of CaliforniaInventor: C. Anthony Hunt
-
Patent number: 4529561Abstract: Liposomes of uniform size are produced by forming liposomes in relatively random sizes, and extruding the liposomes under pressure through a uniform-pore-size membrane to force at least some of the liposomes into smaller sizes. Extrusion may be repeated to increase uniformity of the liposomes. The liposomes may contain an encapsulated drug.Type: GrantFiled: January 21, 1983Date of Patent: July 16, 1985Assignee: The Regents of the University of CaliforniaInventors: C. Anthony Hunt, Demetrios P. Papahadjopoulous
-
Patent number: 4425334Abstract: Functional oxygen transport systems (OTS) have been devised which may serve as temporary blood substitutes in the circulatory system. The OTS comprises pure crystalline hemoglobin dissolved in an aqueous solution and encapsulated within a complex lipid and carbohydrate modified lipid phase. The hemoglobin encapsulated inner aqueous phase and the encapsulating lipid phase are dispensed in an outer isotonic aqueous phase to form a suspension of the multiple water-in-oil-in water emulsion type. The emulsion is suitable to transfusion into the circulatory system to assist in oxygen transport. The carbohydrate modified lipids are included in the lipid phase to "mask" the OTS from the tissue binding and take up by the reticuloendothelial system. The OTS are also suitable for use as calibrating fluids in gas analysis apparatus.Type: GrantFiled: April 2, 1982Date of Patent: January 10, 1984Assignee: The Regents of the University of CaliforniaInventor: C. Anthony Hunt
-
Patent number: 4263428Abstract: A new group of compounds having an enhanced ability to inhibit nucleic acid functions have been prepared. These drugs are bis-anthracyclines wherein two anthracycline molecules are linked through their C-13 carbon atoms by amino and/or hydroxy-dicarboxylic acids and their derivatives to form the bis-compounds. Such bis-anthracyclines may be even more effectively delivered to selected sites in a mammalian organism by incorporating the same within uniformly sized liposomes.Type: GrantFiled: February 23, 1979Date of Patent: April 21, 1981Assignee: The Regents of the University of CaliforniaInventors: Martin A. Apple, C. Anthony Hunt, Hiroaki Yanagisawa